Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor

PCSK9 (proprotein convertase subtilisin/kexin type 9) promotes degradation of the LDLR [LDL (low-density lipoprotein) receptor] through an as-yet-undefined mechanism, leading to a reduction in cellular LDLc (LDL-cholesterol) and a concomitant increase in serum LDLc. Central to the function of PCSK9...

Descripción completa

Detalles Bibliográficos
Autores principales: Duff, Christopher J., Scott, Martin J., Kirby, Ian T., Hutchinson, Sue E., Martin, Steve L., Hooper, Nigel M.
Formato: Texto
Lenguaje:English
Publicado: Portland Press Ltd. 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2669217/
https://www.ncbi.nlm.nih.gov/pubmed/19196236
http://dx.doi.org/10.1042/BJ20082407

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2669217/
https://www.ncbi.nlm.nih.gov/pubmed/19196236
http://dx.doi.org/10.1042/BJ20082407

Ejemplares similares